Clayton, Dubilier & Rice is acquiring a majority stake in Humana's (NYSE: HUM) hospice arm in a deal valued at $3.4 billion.
Why it matters: The deal comes just weeks after Optum’s $5.4 billion wager for LHC Group, providing further proof that at-home health care as an end-market, and its providers, play a crucial role in the push towards value-based care, beyond being patients’ preferred setting.
